Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Myriad Genetics (MYGN) over the last 15 years, with Sep 2025 value amounting to $728.1 million.

  • Myriad Genetics' Liabilities and Shareholders Equity fell 32.66% to $728.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 billion, marking a year-over-year decrease of 22.25%. This contributed to the annual value of $1.0 billion for FY2024, which is 10.37% down from last year.
  • According to the latest figures from Q3 2025, Myriad Genetics' Liabilities and Shareholders Equity is $728.1 million, which was up 7.50% from $677.3 million recorded in Q2 2025.
  • Myriad Genetics' Liabilities and Shareholders Equity's 5-year high stood at $1.4 billion during Q2 2021, with a 5-year trough of $677.3 million in Q2 2025.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $1.1 billion (2024), whereas its average is $1.0 billion.
  • Data for Myriad Genetics' Liabilities and Shareholders Equity shows a maximum YoY slumped of 37.58% (in 2025) over the last 5 years.
  • Myriad Genetics' Liabilities and Shareholders Equity (Quarterly) stood at $1.3 billion in 2021, then dropped by 9.24% to $1.2 billion in 2022, then dropped by 4.35% to $1.1 billion in 2023, then fell by 10.37% to $1.0 billion in 2024, then plummeted by 32.66% to $728.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $728.1 million in Q3 2025, compared to $677.3 million in Q2 2025 and $1.0 billion in Q1 2025.